FDA Oncology/X
Aug 20, 2025, 18:17
Draft Guidance on Overall Survival Assessment in Oncology Trials – FDA Oncology
FDA Oncology shared a post on X:
“NEW: FDA releases draft guidance on overall survival assessment in oncology trials, with an emphasis on analyzing overall survival as a pre-specified safety endpoint.”
Bishal Gyawali, Associate Professor at Queen’s University and Associate Editor of the Journal of the National Cancer Institute, shared this post, adding:
“Emphasis on overall survival is good, but as a safety endpoint or as an efficacy endpoint? Safety implies we don’t want to see a worse OS. Efficacy implies we want to see improved OS.”
More posts featuring FDA Oncology and Bishal Gyawali.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 20, 2025, 17:39
Aug 20, 2025, 17:21
Aug 20, 2025, 17:09
Aug 20, 2025, 16:55
Aug 20, 2025, 16:15
Aug 20, 2025, 15:57
Aug 20, 2025, 15:57
Aug 20, 2025, 15:55